MyoKardia Inc Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi Conference Call
שיחת ועידה MyoKardia Inc
MyoKardia Inc Conference call or earnings call will be held on 02/01/2019 via an 800 number (toll-free). During the earnings conference call's session MyoKardia Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact MyoKardia Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
MyoKardia, Inc. (the "Company"), incorporated under the laws of the State of Delaware in 2012, is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy--hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. We have generated several proprietary, orally administered small molecules to address a variety of biomechanical defects that cause disruptions in heart muscle contraction.קרא עוד שיחת ועידה